87930a6f-c400-4ef6-93b2-d01baba20d8e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65.5824777549624
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- WNT_BETA_CATENIN_SIGNALING+0.410
- MYC_TARGETS_V2+0.330
- P53_PATHWAY+0.330
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.270
- ADIPOGENESIS+0.250
- XENOBIOTIC_METABOLISM+0.250
- PEROXISOME+0.240
- FATTY_ACID_METABOLISM+0.230
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- MITOTIC_SPINDLE-0.320
- G2M_CHECKPOINT-0.310
- INFLAMMATORY_RESPONSE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- ALLOGRAFT_REJECTION-0.280
- ANDROGEN_RESPONSE-0.260
- UV_RESPONSE_DN-0.240
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8f673a13-7f81-4685-a415-645ff6b5e2fb | — | — | 0.810 |
| 2 | R1 | — | — | 0.787 |
| 3 | MNG124 | — | — | 0.782 |
| 4 | TCGA-XF-AAMH-01A-11R-A42T-07 | — | — | 0.775 |
| 5 | fcb06f2b-bc4d-406d-82c3-76802c77a75b | — | — | 0.772 |
| 6 | TCGA-86-8674-01A-21R-2403-07 | — | cohortA2 | 0.766 |
| 7 | BS_BJDNWMJH | Spinal Cord Ependymoma | — | 0.764 |
| 8 | R20 | — | — | 0.762 |
| 9 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.753 |
| 10 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |